Results for tag: "Metastatic Ovarian Cancer Drug"

The Metastatic Ovarian Cancer Drug market is a subset of the larger Ovarian Cancer Drug market. It is composed of drugs used to treat metastatic ovarian cancer, which is cancer that has spread beyond the ovaries to other parts of the body. These drugs are typically used in combination with surgery and chemotherapy to treat the disease. Common drugs used in this market include bevacizumab, olaparib, and niraparib. The Metastatic Ovarian Cancer Drug market is highly competitive, with many companies vying for market share. Some of the major players in this market include AstraZeneca, Merck & Co., Pfizer, Novartis, and Eli Lilly. Other companies such as AbbVie, Amgen, and Bristol-Myers Squibb also have a presence in this market. Show Less Read more